Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine

International Journal of Neuropsychopharmacology

Volumn 14, Issue 1, 2011, Pages 17-28

  Guidali, Cinzia ^a   Viganò, Daniela ^a,b   Petrosino, Stefania ^c   Zamberletti, Erica ^a   Realini, Natalia ^a   Binelli, Giorgio ^a   Rubino, Tiziana ^a   Di Marzo, Vincenzo ^c   Parolaro, Daniela ^a,b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b Zardi Gori Foundation   (Italy)

^c CNR   (Italy)

Author keywords

AM251 antipsychotic activity; chronic phencyclidine; endocannabinoid system; rat; schizophrenia

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; CANNABINOID 1 RECEPTOR; CLOZAPINE; ENDOCANNABINOID; PHENCYCLIDINE; PROTEIN C FOS; AMINO ACID RECEPTOR BLOCKING AGENT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CEREBELLUM; CHEMICAL ANALYSIS; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; FORCED SWIMMING TEST; GLOBUS PALLIDUS; HIPPOCAMPUS; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; LIPID BRAIN LEVEL; MALADJUSTMENT; MALE; MEMORY; NEGATIVE SYNDROME; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RECEPTOR DENSITY; SUBSTANTIA NIGRA; THALAMUS; TREATMENT DURATION; VENTRAL TEGMENTUM; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; SCHIZOPHRENIA; TIME;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; PIPERIDINES; PREFRONTAL CORTEX; PYRAZOLES; RATS; RECEPTOR, CANNABINOID, CB1; SCHIZOPHRENIA; TIME FACTORS;

EID: 79952748303     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710000209     Document Type: Article

References (61)

1. Abdel-Naby Sayed M, Noda Y, Mahmoud Hamdy M, Mamiya T, et al. (2001). Enhancement of immobility induced by repeated phencyclidine injection: association with c-Fos protein in the mouse brain. Behavioral Brain Reserach 124, 71-76. (Pubitemid 32567560)
2. Ballmaier M, Bortolato M, Rizzetti C, Zoli M, et al. (2007). Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology 32, 2098-2107. (Pubitemid 47417693)
3. Barker GR, Bird F, Alexander V, Warburton EC (2007). Recognition memory for objects, place, and temporal order: a disconnection analysis of the role of the medial prefrontal cortex and perirhinal cortex. Journal of Neuroscience 27, 2948-2957. (Pubitemid 46438982)
4. Bartha R, Williamson PC, Drost DJ, Malla A, et al. (1997). Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Archives for General Psychiatry 54, 959-965. (Pubitemid 28022747)
5. Bast T, Feldon J (2003). Hippocampal modulation of sensorimotor processes. Progress in Neurobiology 70, 319-345. (Pubitemid 37107357)
6. Bisogno T, Sepe N, Melck D, Maurelli S, et al. (1997). Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochemical Journal 322, 671-677. (Pubitemid 27116599)
7. Bubeníková-Valesová V, Horácek J, Vrajová M, Höschl C (2008). Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neuroscience and Biobehavioral Review 32, 1014-1023. (Pubitemid 351756510)
8. Cochran SM, Kennedy M, McKerchar CE, Steward LJ, et al. (2003). Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28, 265-275.
9. De Marchi N, De Petrocellis L, Orlando P, Daniele F, et al. (2003). Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids in Health and Disease 2, 5-14.
10. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103, 9-15. (Pubitemid 32304342)
11. Dere E, Huston JP, De Souza Silva MA (2007). The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neuroscience and Biobehavioural Review 31, 673-704. (Pubitemid 46670336)
12. Devane WA, Hanus L, Breuer A, Pertwee RG, et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949. (Pubitemid 23026736)
13. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, et al. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 57, 594-608. (Pubitemid 40409699)
14. Dragunow M, Faull RL (1990). MK801 induces c-fos protein in thalamic and neocortical neurons of rat brain. Neuroscience Letters 113, 144-150. (Pubitemid 20180676)
15. Duncan GE, Moy SS, Knapp DJ, Mueller RA, et al. (1998). Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Research 787, 181-190. (Pubitemid 28197904)
16. Egerton A, Reid L, McGregor S, Cochran SM, et al. (2008). Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats. Psychopharmacology 198, 37-49.
17. Filipkowski RK, Rydz M, Berdel B, Morys J, et al. (2000). Tactile experience induces c-fos expression in rat barrel cortex. Learning and Memory 7, 116-122. (Pubitemid 30213025)
18. Gerdeman GL, Ronesi J, Lovinger DM (2002). Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nature Neuroscience 5, 446-451. (Pubitemid 34454250)
19. Gessa GL, Casu MA, Carta G, Mascia MS (1998). Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. European Journal of Pharmacology 355, 119-124. (Pubitemid 28404693)
20. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, et al. (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29, 2108-2114. (Pubitemid 39486563)
21. Gray JA, Roth BL (2007). Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophrenia Bulletin 33, 1100-1119. (Pubitemid 47347917)
22. Green AI (2005). Schizophrenia and comorbid substance use disorder: effects of antipsychotics. Journal of Clinical Psychiatry 6, 21-26. (Pubitemid 41243258)
23. Haller J, Szirmai M, Varga B, Ledent C, et al. (2005). Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behavioural Pharmacology 16, 415-422. (Pubitemid 41404813)
24. Heffner TG, Hartman JA, Seiden LS (1980). A rapid method for the regional dissection of the rat brain. Pharmacology Biochemistry and Behavior 13, 453-456. (Pubitemid 10008987)
25. Herrera DG, Robertson HA (1996). Activation of c-fos in the brain. Progress in Neurobiology 50, 83-107. (Pubitemid 26412595)
26. Ichikawa J, Li Z, Dai J, Meltzer HY (2002). Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Research 956, 349-357. (Pubitemid 35351402)
27. Jenkins TA, Harte MK, McKibben CE, Elliott JJ, et al. (2008). Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat. Behavioral Brain Research 194, 230-235.
28. Kondziella D, Brenner E, Eyjolfsson EM, Markinhuhta KR, et al. (2006). Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure. Neuropsychopharmacology 31, 1880-1887.
29. Leweke FM, Giuffrida A, Koethe D, Schreiber D, et al. (2007). Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophrenia Research 94, 29-36. (Pubitemid 47031599)
30. Leweke FM, Giuffrida A, Wurster U, Emrich HM, et al. (1999). Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10, 1665-1669. (Pubitemid 29354290)
31. Malone DT, Long LE, Taylor DA (2004). The effect of SR 141716 and apomorphine on sensorimotor gating in Swiss mice. Pharmacology Biochemistry and Behavior 77, 839-845. (Pubitemid 38510296)
32. Marsicano G, Wotjak CT, Azad SC, Bisogno T, et al. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530-534. (Pubitemid 34851398)
33. Martin SD, Libretto SE, Pratt DJ, Brewin JS, et al. (2003). Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Current Medical Research and Opinion 19, 298-305. (Pubitemid 36827838)
34. Meltzer HY, Arvanitis L, Bauer D, Rein W (2004). Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. American Journal of Psychiatry 161, 975-984. (Pubitemid 38735983)
35. Mouri A, Noda Y, Enomoto T, Nabeshima T (2007). Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochemistry International 51, 173-184. (Pubitemid 47176714)
36. Newell KA, Deng C, Huang XF (2006). Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Experimental Brain Research 172, 556-560. (Pubitemid 43989359)
37. Noda Y, Kamei H, Mamiya T, Furukawa H, et al. (2000). Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 23, 375-387.
38. Noda Y, Mamiya T, Furukawa H, Nabeshima T (1997). Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. European Journal of Pharmacology 324, 135-140. (Pubitemid 27174597)
39. Noda Y, Yamada K, Furukawa H, Nabeshima T (1995). Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. British Journal of Pharmacology 116, 2531-2537.
40. O'Tuathaigh CM, Kirby BP, Moran PM, Waddington JL (2009). Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia. Schizophrenia Bulletin. Published online: 24 November 2009. doi:10.1093/schbul/ sbp125.
41. Pencer A, Addington J, Addington D (2005). Outcome of a first episode of psychosis in adolescence: a 2-year follow-up. Psychiatry Research 133, 35-43.
42. Porsolt RD, Anton G, Blavet N, Jalfre M (1978). Behavioural despair in rats: a new model sensitive to antidepressant treatments. European Journal of Pharmacology 47, 379-391.
43. Potvin S, Kouassi E, Lipp O, Bouchard RH, et al. (2008). Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. Journal of Psychopharmacology 22, 262-269. (Pubitemid 351847449)
44. Pratt JA, Winchester C, Egerton A, Cochran SM, et al. (2008). Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. British Journal of Pharmacology 153 (Suppl. 1), 465-470.
45. Robbe D, Kopf M, Remaury A, Bockaert J, et al. (2002). Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proceedings of the National Academy of Sciences USA 99, 8384-8388. (Pubitemid 34651061)
46. Roser P, Vollenweider FX, Kawohl W (2008). Potential antipsychotic properties of central cannabinoid (CB(1)) receptor antagonists. World Journal of Biological Psychiatry 7, 1-12.
47. Rubino T, Patrini G, Parenti M, Massi P, et al. (1997). Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. Molecular Brain Research 44, 191-197. (Pubitemid 27102847)
48. Rubino T, Viganò D, Costa B, Colleoni M, et al. (2000). Loss of cannabinoid-stimulated guanosine 5(-O-(3-[(35)S]Thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats. Journal of Neurochemistry 75, 2478-2484.
49. Seillier A, Advani T, Cassano T, Hensler JG, et al. (2009). Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. International Journal of Neuropsychopharmacology 17, 1-14.
50. Shirazi-Southall S, Rodriguez DE, Nomikos GG (2002). Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26, 583-594. (Pubitemid 34260977)
51. Sjöström PJ, Turrigiano GG, Nelson SB (2003). Neocortical LTD via coincident activation of presynaptic NMDA and cannabinoid receptors. Neuron 39, 641-654. (Pubitemid 36993581)
52. Straiker A, Mackie K (2005). Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. Journal of Physiology 569, 501-517. (Pubitemid 41830118)
53. Sugita S, Namima M, Nabeshima T, Okamoto K, et al. (1996). Phencyclidine-induced expression of c-Fos-like immunoreactivity in mouse brain regions. Neurochemistry International 28, 545-550. (Pubitemid 26161325)
54. Théberge J, Bartha R, Drost DJ, Menon RS, et al. (2002). Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. American Journal of Psychiatry 159, 1944-1946. (Pubitemid 35283267)
55. Tzavara ET, Davis RJ, Perry KW, Li X, et al. (2003). The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. British Journal of Pharmacology 138, 544-553. (Pubitemid 36315302)
56. Tzavara ET, Li DL, Moutsimilli L, Bisogno T, et al. (2006). Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biological Psychiatry 59, 508-515. (Pubitemid 43320538)
57. Viganò D, Guidali C, Petrosino S, Realini N, et al. (2009). Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. International Journal of Neuropsychopharmacology 12, 599-614.
58. Viganò D, Rubino T, Vaccani A, Bianchessi S, et al. (2005). Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berlin) 182, 527-536. (Pubitemid 41464634)
59. 3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in Neuro- Psychopharmacology & Biological Psychiatry 28, 355-360. (Pubitemid 38130143)
60. Zuo DY, Cao Y, Zhang L, Wang HF, et al. (2009). Effects of acute and chronic administration of MK-801 on c-Fos protein expression in mice brain regions implicated in schizophrenia with or without clozapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33, 290-295.
61. Zuo DY, Zhang YH, Cao Y, Wu CF, et al. (2006). Effect of acute and chronic MK-801 administration on extracellular glutamate and ascorbic acid release in the prefrontal cortex of freely moving mice on line with open-field behaviour. Life Science 78, 2172-2178.